Literature DB >> 31664618

Prognostic Value of Tumor Regression Grade Based on Ryan Score in Squamous Cell Carcinoma and Adenocarcinoma of Esophagus.

Flávio Roberto Takeda1, Francisco Tustumi2, Carlos de Almeida Obregon1, Gustavo Gonçalves Yogolare1, Yasmin Peres Navarro1, Vanderlei Segatelli3, Rubens Antonio Aissar Sallum1, Ulysses Ribeiro Junior1, Ivan Cecconello1.   

Abstract

PURPOSES: Tumor regression grade (TRG) of the primary tumor after neoadjuvant therapy is one of the most sensitive prognostic factors among patients with locally advanced esophageal cancer, although no TRG system is fully accepted. The Ryan score was proposed in 2005 to evaluate TRG in rectal cancer and could be adaptable for pathological evaluation of esophageal cancer. The objective of this study is to evaluate the prognostic value of the Ryan score for esophageal cancer in the setting of trimodal therapy.
METHODS: We performed a retrospective cohort study in which patients with locally advanced esophageal cancer, submitted to neoadjuvant therapy followed by surgical resection, were selected. One hundred thirty-four patients were selected. All tissue specimens were assessed as per the TRG system proposed by Ryan et al. Survival curves were assessed by the Kaplan-Meier method and log-rank test. Chi-square test or likelihood-ratio test was used for absolute and relative variables. Kruskal-Wallis and analysis of variance tests were used to assess significant differences on a continuous dependent variable by a categorical independent variable.
RESULTS: Of the 134 included patients, 94 (70.1%) had squamous cell carcinoma, and 40 (29.9%) adenocarcinoma. Ryan score was correlated with histological type (p < 0.001), and clinical (p = 0.044) and pathological (p < 0.001) staging. Mean follow-up was 31.1 months. Multivariate analysis showed that Ryan score can safely predict survival, and systemic and lymphatic recurrence (p < 0.05).
CONCLUSIONS: Ryan score is an effective system to evaluate TRG and can predict risk for lymph node or distant metastasis, overall survival, and disease-free survival.

Entities:  

Mesh:

Year:  2019        PMID: 31664618     DOI: 10.1245/s10434-019-07967-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  7 in total

1.  NEOADJUVANT CHEMORADIOTHERAPY FOLLOWED BY TRANSHITAL ESOPHAGECTOMY IN LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: IMPACT OF PATHOLOGICAL COMPLETE RESPONSE.

Authors:  Iuri Pedreira Fillardi Alves; Valdir Tercioti Junior; João de Souza Coelho Neto; José Antonio Possatto Ferrer; José Barreto Campello Carvalheira; Eduardo Baldon Pereira; Luiz Roberto Lopes; Nelson Adami Andreollo
Journal:  Arq Bras Cir Dig       Date:  2022-01-05

2.  A clinical nomogram for predicting tumor regression grade in esophageal squamous-cell carcinoma treated with immune neoadjuvant immunotherapy.

Authors:  Yongkui Yu; Wei Wang; Zimin Qin; Haomiao Li; Qi Liu; Haibo Ma; Haibo Sun; Thomas L Bauer; Jose M Pimiento; Emmanuel Gabriel; Thomas Birdas; Yin Li; Wenqun Xing
Journal:  Ann Transl Med       Date:  2022-01

3.  Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy.

Authors:  Mashiro Okunaka; Daisuke Kotani; Ken Demachi; Hisashi Fujiwara; Shingo Sakashita; Takayuki Yoshino; Takeo Fujita; Takashi Kojima
Journal:  Esophagus       Date:  2021-10-05       Impact factor: 4.230

4.  A novel prognostic model: which group of esophageal squamous cell carcinoma patients could benefit from adjuvant chemotherapy.

Authors:  Zihao Zhou; Shujie Huang; Xiaosong Ben; Weitao Zhuang; Liangli Hong; Zefeng Xie; Dongkun Zhang; Liang Xie; Haiyu Zhou; Jiming Tang; Gang Chen; Hansheng Wu; Guibin Qiao
Journal:  Ann Transl Med       Date:  2022-02

5.  Trimodal Therapy in Esophageal Squamous Cell Carcinoma: Role of Adjuvant Therapy Following Neoadjuvant Chemoradiation and Surgery.

Authors:  Xiaokun Li; Siyuan Luan; Yushang Yang; Jianfeng Zhou; Qixin Shang; Pinhao Fang; Xin Xiao; Hanlu Zhang; Yong Yuan
Journal:  Cancers (Basel)       Date:  2022-07-30       Impact factor: 6.575

6.  Tumor Regression Grade Predicts Survival in Locally Advanced Gastric Adenocarcinoma Patients with Lymph Node Metastasis.

Authors:  Yilin Tong; Yanmei Zhu; Yan Zhao; Zexing Shan; Jianjun Zhang; Dong Liu
Journal:  Gastroenterol Res Pract       Date:  2020-07-18       Impact factor: 2.260

7.  Comparative analysis of long-term oncologic outcomes for minimally invasive and open Ivor Lewis esophagectomy after neoadjuvant chemoradiation: a propensity score matched observational study.

Authors:  Robert E Merritt; Peter J Kneuertz; Mahmoud Abdel-Rasoul; Desmond M D'Souza; Kyle A Perry
Journal:  J Cardiothorac Surg       Date:  2021-12-06       Impact factor: 1.637

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.